ArticleMediastinum (Hong Kong, China)2019
Deciphering the biology of thymic epithelial tumors.
Article in Mediastinum (Hong Kong, China), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- A Rare Histologic Variant of Thymoma: Diagnostic Challenges of Micronodular Thymoma With Lymphoid Stroma.Cureus · 2026Article
- When Central Tolerance Fails: Thymic Malignancies at the Intersection of Cancer Immunity and Autoimmunity.Cancers · 2026Review
- Current Clinical Paradigm and Therapeutic Advancements in Thymic Malignancies: A Narrative Review.Cancers · 2025Review
- An extremely rare case of thymic carcinoma manifesting as a liver metastasis: a case report and literature review.Discover oncology · 2025Article
- Prognostic impact of surgery on thymic malignancies with concurrent or previous extrathymic malignancies: a retrospective analysis from 1998 to 2021.Journal of cardiothoracic surgery · 2025Article
- Genetic profile of thymic epithelial tumors in the Japanese population: an exploratory study examining potential therapeutic targets.Translational lung cancer research · 2023Article
- Review
- Clinicogenomic Landscape of Metastatic Thymic Epithelial Tumors.JCO precision oncology · 2023Article
- The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?Cancers · 2022Review
- Identification of Immune-Related Hub Genes in Thymoma: Defects in CD247 and Characteristics of Paraneoplastic Syndrome.Frontiers in genetics · 2022Article
- Molecular pathology of thymomas: implications for diagnosis and therapy.Virchows Archiv : an international journal of pathology · 2021Review
- Autoimmune disorders and paraneoplastic syndromes in thymoma.Journal of thoracic disease · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Thymic cancers arise from epithelial cells of the thymus and have a predilection for intrathoracic spread. Clinical behavior varies from relatively indolent to highly aggressive with a capacity to metastasize widely and adversely affect survival. Paraneoplastic autoimmune disorders are frequently observed in association with thymoma and have a significant impact on quality of life. Underlying immune deficits associated with thymic epithelial tumors (TETs) increase the risk for development of opportunistic infections and emergence of extrathymic malignancies. Advances in the molecular characterization of thymic tumors have revealed the lowest tumor mutation burden among all adult cancers and the occurrence of distinct molecular subtypes of these diseases. Mutations in general transcription factor IIi (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.